APIs for research and impurities

<p>Tacrolimus is a macrolide that is used as an immunosuppressive drug. It has been shown to bind to the FK-binding protein, which in turn inhibits calcineurin. This prevents the release of IL-2, TNF-α and other cytokines. The immunosuppressive effects of tacrolimus have been evaluated using analytical methods such as coefficients, affinity, and monitoring techniques such as immunoassays and agglutination. These techniques are used to evaluate the plasma concentration of tacrolimus. Tacrolimus also binds to proteins in the blood samples and can be detected by turbidimetric or electrochemiluminescence immunoassay reagents.</p>

<p>Please enquire for more information about Acrolein-d4 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Xanthoxin is a medicinal compound with potent anticancer properties. It has been shown to induce apoptosis, or programmed cell death, in cancer cells. Xanthoxin has been tested in various cancer cell lines, including Chinese and human cells, and has demonstrated strong inhibitory effects on the tumor cycle. This compound works by inhibiting kinases and other proteins involved in cancer cell growth and proliferation. Xanthoxin is also known to be an inhibitor of certain urinary proteins that are associated with cancer progression. Overall, Xanthoxin shows great potential as a natural product for the development of novel anticancer therapies.</p>

<p>S(-)-BZM is a potent kinase inhibitor that has been shown to induce apoptosis in cancer cells. It is an analog of the natural product staurosporine and has been isolated from human urine. S(-)-BZM inhibits the activity of several kinases, including protein kinase C and cyclin-dependent kinases, which are involved in cell cycle regulation and tumor growth. This drug has been tested on various cancer cell lines, including leukemia, and has demonstrated significant antitumor activity. S(-)-BZM is a promising medicinal agent for the treatment of cancer and other diseases characterized by abnormal cell proliferation.</p>

<p>N-Desmethyl trimeprazine is a synthetic compound, which is an impurity of the drug product. It is not active and does not possess any biological activity. It is a metabolite of the parent drug, Trimeprazine. N-Desmethyl trimeprazine has been studied for its pharmacological properties and metabolism in the body, but no conclusive results have been found. The chemical structure and purity of N-Desmethyl trimeprazine are not listed in the USP or BP. This compound can be custom synthesized on request.</p>

<p>Pirtenidine is a potent and selective kinase inhibitor that has been shown to inhibit the activity of cyclin-dependent kinases. It has demonstrated promising results in preclinical studies as an anticancer agent, inducing apoptosis in cancer cells. Pirtenidine is an analog of protein kinase inhibitors, which have been used to treat various types of tumors. It has been found to be effective against human cancer cell lines and has shown significant tumor growth inhibition in animal models. Pirtenidine has also been reported to be a potent urine inhibitor of Chinese hamster ovary cells, making it a promising candidate for the treatment of urinary tract cancers.</p>

<p>Bezafibrate is a drug product that is used in the treatment of hyperlipidemia. It is an impurity standard for bezafibrate 1-o-β-glucuronide, which can be used as an analytical standard for HPLC analysis. Bezafibrate 1-o-β-glucuronide can also be used to evaluate the metabolism of bezafibrate through animal studies.</p>

<p>Pemetrexed is an antifolate drug that is used to treat cancer. It is a prodrug of pemetrexed disodium, which is converted to pemetrexed in the body by esterases. Pemetrexed is metabolized to its active form, D-pemetrexed, which inhibits DNA synthesis and the growth of cells by inhibiting thymidylate synthase. D-Pemetrexed hydrate is a high purity, pharmacopoeia grade impurity standard for use in research and development or as a custom synthesis. It has been shown to inhibit the growth of certain types of cancer cells and can be used in combination with other treatments such as chemotherapy or radiation therapy.</p>

<p>Benquinox is a potent inhibitor of protein kinases that has shown promise in the treatment of cancer. It works by blocking the activity of certain kinases that are involved in cell growth and division, leading to apoptosis (programmed cell death) in cancer cells. Benquinox is an analog of donepezil, a drug used to treat Alzheimer's disease. Studies have shown that Benquinox inhibits tumor growth and induces apoptosis in human cancer cell lines. It has also been found to be effective against urinary tract tumors in Chinese patients. As an anticancer agent, Benquinox is being investigated for its potential use as a targeted therapy for various types of cancer. Its ability to inhibit kinases makes it a promising candidate for combination therapies with other kinase inhibitors.</p>